| MeSH term | MeSH ID | Detail |
|---|---|---|
| Ureteral Obstruction | D014517 | 10 associated lipids |
| Rodent Diseases | D012376 | 4 associated lipids |
| Osteomyelitis | D010019 | 10 associated lipids |
| Pancreatitis | D010195 | 10 associated lipids |
| Skin Ulcer | D012883 | 6 associated lipids |
| Cysts | D003560 | 4 associated lipids |
| Urination Disorders | D014555 | 9 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- FEMS Immunol. Med. Microbiol. (1)
- J. Antimicrob. Chemother. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Anzueto A et al. | The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. | 1999 | Clin. Infect. Dis. | pmid:10451195 |
| Gordin FM et al. | A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. | 1999 | Clin. Infect. Dis. | pmid:10452638 |
| Pandita D and Carson PJ | Thyroid abscess caused by Mycobacterium chelonae. | 1999 | Clin. Infect. Dis. | pmid:10452671 |
| Härtig G et al. | [Symptomatic psychosis in bland sinus thrombosis and antibiotic therapy]. | 1999 | Psychiatr Prax | pmid:10457975 |
| Labenz J and Stolte M | [Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?]. | 1999 | Z Gastroenterol | pmid:10458014 |
| Boyanova L et al. | Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. | 1999 | Diagn. Microbiol. Infect. Dis. | pmid:10459482 |
| Sendi PP et al. | Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. | 1999 | J Eval Clin Pract | pmid:10461580 |
| Gooderham MJ et al. | Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. | 1999 Jul-Aug | Ann Pharmacother | pmid:10466907 |
| Gschwantler M et al. | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468682 |
| Paré P et al. | Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468683 |
| Sung JJ et al. | One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468684 |
| Catalano F et al. | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. | 1999 | Helicobacter | pmid:10469192 |
| Kamada T et al. | Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. | 1999 | Helicobacter | pmid:10469195 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Tanaka E et al. | Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. | 1999 | Am. J. Respir. Crit. Care Med. | pmid:10471610 |
| Mikamo H et al. | Adequate macrolide treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. | 1999 Sep-Oct | Chemotherapy | pmid:10473928 |
| Geiderman JM | Central nervous system disturbances following clarithromycin ingestion. | 1999 | Clin. Infect. Dis. | pmid:10476775 |
| Gómez Cubillos C et al. | [Can macrolide treatment delay the diagnosis of tuberculosis?]. | 1999 | An Med Interna | pmid:10481348 |
| Sato K et al. | [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines]. | 1999 | Kekkaku | pmid:10481412 |
| Gidoh M | [The control leprous peripheral neuropathy and chemotherapy]. | 1999 | Nihon Hansenbyo Gakkai Zasshi | pmid:10481449 |
| Klapper SR and Patrinely JR | Periocular atypical mycobacterial infections. | 1999 | Ophthalmology | pmid:10485521 |
| Matsuoka M et al. | Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. | 1999 | Gut | pmid:10486356 |
| Tyagi AK et al. | An unreported side effect of topical clarithromycin when used successfully to treat Mycobacterium avium-intracellulare keratitis. | 1999 | Cornea | pmid:10487437 |
| RodrÃguez Téllez M et al. | Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. | 1999 | Rev Esp Enferm Dig | pmid:10491487 |
| Gutiérrez-Cabano CA and Raynald AC | Gastroprotective effect of intragastric clarithromycin against damage induced by ethanol in rats. | 1999 | Dig. Dis. Sci. | pmid:10492159 |
| Moore PA | Dental therapeutic indications for the newer long-acting macrolide antibiotics. | 1999 | J Am Dent Assoc | pmid:10492541 |
| Osato MS et al. | Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. | 1999 | Int. J. Antimicrob. Agents | pmid:10493611 |
| Hirsh DC and Jang SS | Antimicrobial susceptibility of Nocardia nova isolated from five cats with nocardiosis. | 1999 | J. Am. Vet. Med. Assoc. | pmid:10496134 |
| Ellenrieder V et al. | Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. | 1999 | Scand. J. Gastroenterol. | pmid:10499474 |
| Zgoulli S et al. | Microencapsulation of erythromycin and clarithromycin using a spray-drying technique. | 1999 Sep-Oct | J Microencapsul | pmid:10499837 |
| Landesman KA et al. | Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. | 1999 | Conn Med | pmid:10500341 |
| Gómez G et al. | Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. | 1999 | Transplant. Proc. | pmid:10500563 |
| Unge P | The OAC and OMC options. | 1999 | Eur J Gastroenterol Hepatol | pmid:10503817 |
| Spiller RC | Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? | 1999 | Eur J Gastroenterol Hepatol | pmid:10503819 |
| Mégraud F | Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. | 1999 | Eur J Gastroenterol Hepatol | pmid:10503821 |
| Bazzoli F et al. | What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? | 1999 | Eur J Gastroenterol Hepatol | pmid:10503822 |
| Gisbert JP et al. | Re-treatment after Helicobacter pylori eradication failure. | 1999 | Eur J Gastroenterol Hepatol | pmid:10503846 |
| Uygun A et al. | Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. | 1999 | Clin Ther | pmid:10509849 |
| McMullin ST et al. | Impact of a Web-based clinical information system on cisapride drug interactions and patient safety. | 1999 | Arch. Intern. Med. | pmid:10510994 |
| Furuta T et al. | Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. | 1999 | Clin. Pharmacol. Ther. | pmid:10511062 |
| Galil K et al. | Abscesses due to mycobacterium abscessus linked to injection of unapproved alternative medication. | 1999 Sep-Oct | Emerging Infect. Dis. | pmid:10511524 |
| Talley NJ et al. | Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. | 1999 | N. Engl. J. Med. | pmid:10511608 |
| Gilljam M et al. | Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. | 1999 | Eur. Respir. J. | pmid:10515412 |
| Rovira E et al. | Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. | 1999 | Respiration | pmid:10516537 |
| Foster SF et al. | Chronic pneumonia caused by Mycobacterium thermoresistibile in a cat. | 1999 | J Small Anim Pract | pmid:10516950 |
| Goldberg EI et al. | Henoch-Schönlein purpura induced by clarithromycin. | 1999 | Int. J. Dermatol. | pmid:10517691 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Gibson JR et al. | Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. | 1999 | J. Clin. Microbiol. | pmid:10523591 |
| Baylor P and Williams K | Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy. | 1999 | Clin. Infect. Dis. | pmid:10525003 |
| Yoh M et al. | Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. | 1999 | Can. J. Microbiol. | pmid:10526400 |